Pharmacology and Clinical Development of Factor XI Inhibitors
Circulation · 14.03.2023 · 147 (11) · 897-913
DOI: 10.1161/circulationaha.122.062353 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 14.03.2023. Verfasst von Antonio Greco und 12 weiteren Autor:innen. Beteiligte Einrichtung: A.O.U. Policlinico "G. Rodolico - San Marco", University of Catania, Italy. Hauptthemen laut MEDLINE: Venous Thromboembolism, Thrombosis, Stroke. Die Arbeit wurde bisher 154-mal zitiert (Crossref) und nennt 99 Literaturangaben.
Abstract (Originalsprache)
Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in several fields of medicine to prevent or treat venous and arterial thromboembolism. According to the different mechanisms of action, the available parenteral and oral anticoagulant drugs share the common principle of hampering or blocking key steps of the coagulation cascade, which unavoidably comes at the price of an increased propensity to bleed. Hemorrhagic complications affect patient prognosis both directly and indirectly (ie, by preventing the adoption of an effective antithrombotic strategy). Inhibition of factor XI (FXI) has emerged as a strategy with the potential to uncouple the pharmacological effect and the adverse events of anticoagulant therapy. This observation is based on the differential contribution of FXI to thrombus amplification, in which it plays a major role, and hemostasis, in which it plays an ancillary role in final clot consolidation. Several agents were developed to inhibit FXI at different stages (ie, suppressing biosynthesis, preventing zymogen activation, or impeding the biological action of the active form), including antisense oligonucleotides, monoclonal antibodies, small synthetic molecules, natural peptides, and aptamers. Phase 2 studies of different classes of FXI inhibitors in orthopedic surgery suggested that dose-dependent reductions in thrombotic complications are not paralleled by dose-dependent increases in bleeding compared with low-molecular-weight heparin. Likewise, the FXI inhibitor asundexian was associated with lower rates of bleeding compared with the activated factor X inhibitor apixaban in patients with atrial fibrillation, although no evidence of a therapeutic effect on stroke prevention is available so far. FXI inhibition could also be appealing for patients with other conditions, including end-stage renal disease, noncardioembolic stroke, or acute myocardial infarction, for which other phase 2 studies have been conducted. The balance between thromboprophylaxis and bleeding achieved by FXI inhibitors needs confirmation in large-scale phase 3 clinical trials powered for clinical end points. Several of such trials are ongoing or planned to define the role of FXI inhibitors in clinical practice and to clarify which FXI inhibitor may be most suited for each clinical indication. This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, and future perspectives of drugs inhibiting FXI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- A.O.U. Policlinico "G. Rodolico - San Marco", University of Catania, Italy.
ORCID-Profile: Antonio Greco, Claudio Laudani, Marco Legnazzi, Maria Sara Mauro, Davide Capodanno
Zitieren
APA
Greco, A., Laudani, C., Spagnolo, M., Agnello, F., Faro, D. C., Finocchiaro, S., Legnazzi, M., Mauro, M. S., Mazzone, P. M., Occhipinti, G., Rochira, C., Scalia, L., & Capodanno, D. (2023). Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation, 147(11), 897-913. https://doi.org/10.1161/circulationaha.122.062353
Vancouver
Greco A, Laudani C, Spagnolo M, Agnello F, Faro DC, Finocchiaro S, et al. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023;147(11):897-913. doi:10.1161/circulationaha.122.062353
BibTeX
@article{Greco2023,
author = {Greco, Antonio and Laudani, Claudio and Spagnolo, Marco and Agnello, Federica and Faro, Denise Cristiana and Finocchiaro, Simone and Legnazzi, Marco and Mauro, Maria Sara and Mazzone, Placido Maria and Occhipinti, Giovanni and Rochira, Carla and Scalia, Lorenzo and Capodanno, Davide},
title = {Pharmacology and Clinical Development of Factor XI Inhibitors},
journal = {Circulation},
year = {2023},
volume = {147},
number = {11},
pages = {897--913},
doi = {10.1161/circulationaha.122.062353}
}
EUVIMED